No longer availableExpanded AccessUpdated Mar 12, 2024
Expanded Access Neoantigen Vaccine in Solid Tumors
Expanded Access Neoantigen Vaccine in Solid Tumors
ClinicalTrials.gov ID
NCT03914872
Lead Sponsor
Washington University School of MedicineOTHER
Overall Status
No longer available
Study Type
Expanded Access
Last Update Posted
Mar 12, 2024Actual
Official Title
Expanded Access Neoantigen Vaccine in Solid Tumors
Brief Summary
This is an expanded access use study. Safety data will be collected from participants.
Solid Tumor, Adult
Neoantigen DNA Vaccine
Integrated electroporation device
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of a solid tumor
Pathology review demonstrates tumor cellularity of >30% in quantities sufficient to complete DNA and RNA library construction
At least 18 years of age.
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
Able to understand and willing to sign an IRB approved written informed consent document.
Exclusion Criteria:
Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.
Acute or chronic, clinically significant hematologic, pulmonary, cardiovascular, hepatic renal, and/or other functional abnormality that would jeopardize the health and safety of the participant as determined by the investigator based on medical history, physical examination, laboratory values, and/or diagnostic studies.
History of syncopal or vasovagal episode as determined by medical record and history in the 12 month period prior to first vaccination administration.
Individuals in whom a skinfold measurement of the cutaneous and subcutaneous tissue for eligible injection sites (left and right medial deltoid region) exceeds 40 mm.
Individuals in whom the ability to observe possible local reactions at the eligible injection sites (deltoid region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art.
Therapeutic or traumatic metal implant in the skin or muscle of either deltoid region.
Any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child.
Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.